Point of Care Diagnostics Market: Growth, Size, Share, and Trends

Report Code MD 2702
Published in Jan, 2025, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

Point of Care Diagnostics Market by Product (Glucose, Infectious Disease (TB, HAI, STD), Pregnancy), Purchase Mode (Rx, OTC), Technology (Biochemistry, MDx (RT-PCR, INAAT)), Sample (Blood, Urine), End User (Home Care, Hospitals) - Global Forecast to 2029

Overview

The global point of care diagnostics market, valued at US$14.26 billion in 2023, is forecasted to grow at a robust CAGR of 8.5%, reaching US$15.05 billion in 2024 and an impressive US$22.63 billion by 2029. The growing prevalence of chronic diseases, such as diabetes has necessitated a need for routine monitoring with early and timely detection. Since these conditions need to be constantly monitored, the demand for quick, effective, and appropriate testing methods have expanded. For instance, increasing demand for POC diagnostics like glucose monitoring products is because of the easy, quick results, which patients get, helping them to take care of the disease and make an early intervention. Government initiatives promoting POC testing, including investments in health care innovation are also contributing to increased market growth.

Point of Care Diagnostics Market – Global Forecast and Key Opportunities to 2029

Attractive Opportunities in the Point of Care Diagnostics Market

Asia Pacific

Market growth in the Asia Pacific can be attributed to the improving healthcare infrastructure, rising chronic and infectious disease prevalence, and economic growth in developing countries in the region.

The market is driven by the increasing global burden of chronic and infectious diseases, supportive government policies, and the rising number of CLIA approvals for POC tests.

Emerging markets, healthcare decentralization, and growing investments for product development are expected to offer growth opportunities for market players during the forecast period.

The Asia Pacific point of care diagnostics market is expected to be worth USD 5.75 billion by 2029, growing at CAGR of 11.2% during the forecast period.

Product approvals and partnerships were the most widely adopted growth strategies by market players.

Global Point of Care Diagnostics Market Dynamics

DRIVER: Rising availability of CLIA waived point of care tests

Increasing accessibility of CLIA-waived POC tests is greatly supporting the expansion of the POC diagnostics market. Due to the simplicity of CLIA-waived tests, healthcare providers are allowed to carry out diagnostic tests in a variety of settings, as they don't require specific training or specialized facilities and allow health providers to deliver results right on the spot, a feature very important for patients who need prompt diagnosis and treatment. The increasing number of CLIA-waived POC tests is also an essential driver for the growth of the market.

RESTRAINT: Stringent approval process for commercialization of products

Product commercialization in the point of care diagnostics market is relatively limited by the rigid regulatory approval process. Since these products directly reach the point of care from the healthcare providers to the patient, they require stringent safety, accuracy, and performance standards. Testing, documentation, and clinical trials have to be passed by regulatory bodies such as the FDA in the US, CE marking in Europe, and other regional authorities, making sure these products are safe and reliable, which is a rather lengthy and complex process, that translates to delayed time to market, high development cost, and high barriers to entry for small companies.

 

OPPORTUNITY: Increasing inclination towards decentralized healthcare system

As healthcare systems evolve to become less centralized, one of the fastest-growing trends would be to promote the decentralization of testing capacity to healthcare practitioners to conduct point of care diagnoses, which supports much faster decision making through the quick delivery of the test results themselves. Point of care diagnostics will contribute to that shift, making it possible to diagnose and provide treatment to a patient quickly while ensuring accuracy, which is an improvement from the patient care perspective. Moreover, decentralizing diagnostic testing to POC settings also contributes to the timely identification and containment of infectious diseases. Thus, the demand for POC diagnostic solutions is likely to increase, creating substantial opportunities in terms of market growth.

CHALLENGES: Inconsistent standardization with centralized lab methods

Standardization between point of care testing and centralized laboratory methods is one of the major challenges for wider use of point of care diagnostics. Point of care tests may be affected by pre-analytical errors due to improper sampling techniques. Many times, POC tests are performed in emergency situations by nurses or other clinical staff and not by doctors. This makes the chances of errors higher and can have an adverse effect on patient care. Such challenges may hinder POC testing from replacing the traditional methods of the laboratory completely.

Global Point of Care Diagnostics Market Ecosystem Analysis

The point of care diagnostics market thrives on a complex ecosystem. It includes product types, including glucose monitoring products, cardiometabolic monitoring products, infectious disease testing products, coagulation monitoring products, among others that hospitals, physician offices, home care settings and clinical laboratories use. The manufacturers focus on the design and optimization of the products. Distributors include third-party vendors as well as e-commerce platforms. The key stakeholders include the population of patients being diagnosed, the investors, and the regulatory bodies.

Point of Care Diagnostics Market Ecosystem
 

The glucose monitoring products segment accounted for the largest share of the market in 2023, by product

The point of care diagnostics market can be segmented based on product into glucose monitoring products, cardiometabolic monitoring products, infectious disease testing products, coagulation monitoring products, pregnancy & fertility testing products, tumor/cancer marker testing products, urinalysis testing products, cholesterol testing products, hematology testing products, drugs-of-abuse testing products, thyroid stimulating hormone testing products, fecal occult testing products, and other products. Glucose monitoring products is the largest segment in the point of care diagnostics market, mainly attributed to the increase in the incidence of diabetes worldwide. Millions of patients with diabetes globally emphasizes on the need for continuous glucose monitoring through regular blood glucose monitoring, thus sustaining the demand for glucose testing devices that are reliable, accurate, and easy to use. Technology advancement, precision, ease of use, and cost are among the key factors that further increase the adoption rates of glucose monitoring products both by the patient and by healthcare providers.

The biochemistry segment dominated the point of care diagnostics market in 2023, based on technology

On the basis of technology, the point of care diagnostics market has been divided into immunoassays, molecular diagnostics, and biochemistry. Biochemistry accounted for the largest share in the market for point of care diagnostics in 2023. The biochemical markers such as glucose, electrolytes, and lipids need to be diagnosed for chronic conditions like kidney diseases, diabetes, and cardiovascular disease, which account for significant demand for the utilization of biochemistry technology. Biochemistry-based POC devices are the preferred choice for their simplicity, speed, and cost-effectiveness in clinical and home-care settings. Moreover, miniaturized analyzers helped to improve accuracy and usability of the products, hence increasing their demand.

In 2023, North America held the largest share of the Point of Care Diagnostics Market.

The market for point of care diagnostics has been segmented into six major geographical regions: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, and the GCC countries. North America was at the forefront of the market in 2023, on account of its well-established healthcare infrastructure and easy accessibility to advanced diagnostic technologies. Lifestyle diseases such as diabetes are highly prevalent and have consequently increased the demand for rapid, on-the-spot testing solutions. The region also benefits from strong government initiatives for research and product innovation besides regulatory approvals for the development of advanced POC diagnostic products with widespread adoption.

HIGHEST CAGR MARKET IN 2023
NORTH AMERICA FASTEST GROWING MARKET IN THE REGION
Point of Care Diagnostics Market Region

Recent Developments of Point of Care Diagnostics Market

  • In June 2024, bioMérieux (France) received US FDA Special 510(k) clearance and CLIA-waiver for its BIOFIRE SPOTFIRE Respiratory/Sore Throat (R/ST) Panel Mini.
  • In June 2024, F. Hoffmann-La Roche Ltd (Switzerland) acquired LumiraDx’s (US) Point of Care technology to further expand its offering in decentralized patient care and drive global access to timely and actionable diagnostic results.
  • In April 2024, Abbott’s (US) i-STAT TBI cartridge received clearance from the US FDA to be used with whole blood, allowing doctors to help assess patients with suspected concussion at the patient's bedside and obtain lab-quality results in 15 minutes.
  • In December 2023, Thermo Fisher Scientific Inc. (US) and Project HOPE, a leading global health and humanitarian organization, partnered to expand the accessibility of HIV testing services offered by Thermo Fisher among HIV-positive youth in Sub-Saharan Africa.

Key Market Players

Want to explore hidden markets that can drive new revenue in Point of Care Diagnostics Market?

Scope of the Report

Report Metric Details
Market size available for years 2022-2029
Base Year Considered 2023
Forecast period 2024-2029
Forecast units Value (USD) and Volume (Millions)
Segments covered Product, Mode of Purchase, Technology, Sample, and End User
Geographies covered North America, Europe, Asia Pacific, Latin America, Middle East & Africa, and the GCC Countries

 

Key Questions Addressed by the Report

What are the recent trends affecting the point of care diagnostics market?
Recent trends in the point of care diagnostics market include significant technological advancements, rising demand for fast and accurate testing, and the shift towards patient-centered care. The government funding in POC test development and adoption is also picking up, including investments in research, innovation, and infrastructure for new product development, increased accessibility, and reduced costs of testing.
What are the major sample types for point of care diagnostic tests?
Based on sample, the point of care diagnostics market can broadly be divided into blood samples, urine samples, nasal & oropharyngeal swabs, and other samples. Blood samples have dominated the point of care diagnostics market because of their ease of collection, accuracy, and advancements in minimally invasive collection methods such as fingerstick and micro-sampling techniques.
Who are the key players in the point of care diagnostics market?
The key players in this market are Abbott (US), Siemens Healthineers AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Danaher (US), QuidelOrtho Corporation (US), BD (US), Thermo Fisher Scientific Inc. (US), bioMérieux (France), BIOSYNEX SA (France), EKF Diagnostics Holdings plc (UK), Trinity Biotech (Ireland), Werfen (US), Nova Biomedical (US), SEKISUI Diagnostics (US), and Boditech Med Inc. (South Korea).
Who are the major end users of point of care diagnostic products?
The point of care diagnostics market is bifurcated into clinical laboratories, ambulatory care facilities and physician offices, hospitals, critical care centers, and urgent care centers; home care settings and self-testing, and other end users, based on end user. Home care settings and self-testing account for the largest end user segment in the point of care diagnostics market, which is driven by a growing need for convenient, cost-effective, and personalized healthcare solutions.
Which region is lucrative for the point of care diagnostics market?
The Asia Pacific region is one of the most promising regions in the point of care diagnostics market, primarily due to its expanding healthcare infrastructure, increased healthcare expenditure, government initiatives for improving access to healthcare, and awareness of early diagnosis benefits.

 

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Point of Care Diagnostics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
49
RESEARCH METHODOLOGY
55
EXECUTIVE SUMMARY
68
PREMIUM INSIGHTS
74
MARKET OVERVIEW
79
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Growing incidence of infectious diseases
    - Increasing prevalence of chronic diseases
    - Favorable government initiatives for point of care testing
    - Rising number of waived tests
    RESTRAINTS
    - Pricing pressure on manufacturers
    - Stringent regulatory approval process for product commercialization
    OPPORTUNITIES
    - Increasing growth potential in emerging markets
    - Rising inclination toward decentralized healthcare system
    - Booming healthcare spending worldwide
    CHALLENGES
    - Inadequate standardization with centralized lab methods
    - Premium pricing of novel platforms
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.4 PRICING ANALYSIS
    AVERAGE SELLING PRICE, BY PRODUCT
    AVERAGE SELLING PRICE OF GLUCOSE MONITORING TEST STRIPS, BY KEY PLAYER
    AVERAGE SELLING PRICE, BY REGION
    - Average selling price of glucose monitoring test strips, by region
    - Average selling price of infectious disease testing products, by region
    - Average selling price of cardiometabolic monitoring products, by region
  • 5.5 VALUE CHAIN ANALYSIS
  • 5.6 SUPPLY CHAIN ANALYSIS
  • 5.7 ECOSYSTEM ANALYSIS
  • 5.8 INVESTMENT AND FUNDING SCENARIO
  • 5.9 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - Immunoassays
    COMPLEMENTARY TECHNOLOGIES
    - Molecular diagnostics
    ADJACENT TECHNOLOGIES
    - Biochemical technologies
  • 5.10 PATENT ANALYSIS
  • 5.11 TRADE ANALYSIS
    IMPORT DATA FOR HS CODE 3822
    EXPORT DATA FOR HS CODE 3822
  • 5.12 KEY CONFERENCES AND EVENTS, 2025–2026
  • 5.13 PORTER’S FIVE FORCES ANALYSIS
    BARGAINING POWER OF SUPPLIERS
    BARGAINING POWER OF BUYERS
    THREAT OF NEW ENTRANTS
    THREAT OF SUBSTITUTES
    INTENSITY OF COMPETITIVE RIVALRY
  • 5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
    KEY STAKEHOLDERS IN BUYING PROCESS
    KEY BUYING CRITERIA
  • 5.15 IMPACT OF AI ON POINT OF CARE DIAGNOSTICS MARKET
    INTRODUCTION
    MARKET POTENTIAL OF AI IN POINT OF CARE DIAGNOSTICS MARKET
    AI USE CASES
    KEY COMPANIES IMPLEMENTING AI
    FUTURE OF AI IN POINT OF CARE DIAGNOSTICS MARKET
POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT
113
  • 6.1 INTRODUCTION
  • 6.2 GLUCOSE MONITORING PRODUCTS
    GLUCOSE MONITORING STRIPS
    - Growing trend toward preventive healthcare to drive market
    GLUCOSE MONITORING METERS
    - Growing technological advancements in glucose meters to propel market
    GLUCOSE MONITORING LANCETS & LANCING DEVICES
    - Increasing tendency for home-based care and self-monitoring to aid growth
  • 6.3 CARDIOMETABOLIC MONITORING PRODUCTS
    CARDIAC MARKER TESTING PRODUCTS
    - Growing government support for cardiovascular diseases to drive market
    BLOOD GAS/ELECTROLYTE TESTING PRODUCTS
    - Need to optimize hospital workflow to favor growth
    HBA1C TESTING PRODUCTS
    - Increasing recommendations by government healthcare authorities to boost market
  • 6.4 INFECTIOUS DISEASE TESTING PRODUCTS
    RESPIRATORY INFECTION TESTING PRODUCTS
    - Influenza testing products
    - Tuberculosis
    - Other respiratory infection testing products
    HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS
    - Growing rate of surgical-site infections to boost market
    TROPICAL DISEASE TESTING PRODUCTS
    - Rising incidence of malaria and dengue to support growth
    SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS
    - HIV testing products
    - Hepatitis testing products
    - Syphilis testing products
    - Human papillomavirus testing products
    - Chlamydia trachomatis testing products
    - Neisseria gonorrhea testing products
    - Herpes simplex virus testing products
    CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS
    - Rising cases among hospitalized patients to boost demand
    OTHER INFECTIOUS DISEASE TESTING PRODUCTS
  • 6.5 COAGULATION MONITORING PRODUCTS
    PT/INR TESTING PRODUCTS
    - Increasing number of atrial fibrillation cases to accelerate growth
    ACT/APTT TESTING PRODUCTS
    - Rise in surgical procedures to speed up growth
  • 6.6 PREGNANCY & FERTILITY TESTING PRODUCTS
    PREGNANCY TESTING PRODUCTS
    - Increasing awareness about family planning to stimulate growth
    FERTILITY TESTING PRODUCTS
    - Growing infertility issues to fuel market
  • 6.7 TUMOR/CANCER MARKER TESTING PRODUCTS
    GROWING INVESTMENTS IN CANCER RESEARCH TO DRIVE MARKET
  • 6.8 URINALYSIS TESTING PRODUCTS
    INCREASING PREVALENCE OF URINARY TRACT INFECTIONS TO AUGMENT GROWTH
  • 6.9 CHOLESTEROL TESTING PRODUCTS
    RISING OBESITY AND CARDIOVASCULAR DISEASES TO FOSTER GROWTH
  • 6.10 HEMATOLOGY TESTING PRODUCTS
    INCREASING CASES OF ANEMIA TO SUSTAIN GROWTH
  • 6.11 DRUGS-OF-ABUSE TESTING PRODUCTS
    GROWING CONSUMPTION OF ILLICIT DRUGS TO FAVOR MARKET
  • 6.12 THYROID-STIMULATING HORMONE TESTING PRODUCTS
    RISING PREVALENCE OF THYROID TO ENCOURAGE GROWTH
  • 6.13 FECAL OCCULT TESTING PRODUCTS
    GROWING INCIDENCE OF CANCER TO PROPEL MARKET
  • 6.14 OTHER PRODUCTS
POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE
233
  • 7.1 INTRODUCTION
  • 7.2 PRESCRIPTION-BASED TESTING PRODUCTS
    RISING INCIDENCE OF CHRONIC DISEASES TO AUGMENT GROWTH
  • 7.3 OTC TESTING PRODUCTS
    GROWING PATIENT PREFERENCE FOR REMOTE HEALTHCARE TO PROPEL MARKET
POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY
242
  • 8.1 INTRODUCTION
  • 8.2 BIOCHEMISTRY
    INCREASING PREVALENCE OF URINARY TRACT INFECTIONS TO EXPEDITE GROWTH
  • 8.3 IMMUNOASSAYS
    GROWING INCLINATION TOWARD DECENTRALIZED HEALTHCARE TO DRIVE MARKET
  • 8.4 MOLECULAR DIAGNOSTICS
    RT-PCR
    - Growing use of RT-PCR in proteomics and genomics to boost market
    INAAT
    - Emerging new pathogens to facilitate growth
POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE
260
  • 9.1 INTRODUCTION
  • 9.2 BLOOD SAMPLES
    GROWING APPLICATION OF BLOOD SAMPLES IN DISEASE DETECTION TO DRIVE MARKET
  • 9.3 NASAL & OROPHARYNGEAL SWABS
    INCREASING PREVALENCE OF INFECTIOUS DISEASES TO AID GROWTH
  • 9.4 URINE SAMPLES
    NEED FOR EARLY DETECTION AND MONITORING OF DIABETES-RELATED COMPLICATIONS TO PROPEL MARKET
  • 9.5 OTHER SAMPLES
POINT OF CARE DIAGNOSTICS MARKET, BY END USER
276
  • 10.1 INTRODUCTION
  • 10.2 HOME CARE SETTINGS AND SELF-TESTING
    INCREASING PREFERENCE AMONG WOMEN FOR CONFIDENTIALITY AND ACCESSIBILITY TO SUPPORT GROWTH
  • 10.3 CLINICAL LABORATORIES
    GROWING IMPROVEMENTS IN AUTOMATED TESTING SERVICES TO BOOST MARKET
  • 10.4 HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS
    RISING DEMAND FOR FAST DIAGNOSTIC SOLUTIONS TO SPUR GROWTH
  • 10.5 AMBULATORY CARE FACILITIES AND PHYSICIAN OFFICES
    NEED FOR RAPID RESULT GENERATION AND IMMEDIATE PATIENT CARE TO AID GROWTH
  • 10.6 OTHER END USERS
POINT OF CARE DIAGNOSTICS MARKET, BY REGION
292
  • 11.1 INTRODUCTION
  • 11.2 NORTH AMERICA
    MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    US
    - Presence of advanced healthcare infrastructure and high healthcare expenditures to aid growth
    CANADA
    - Rising incidence of diabetes and infectious diseases to support growth
  • 11.3 EUROPE
    MACROECONOMIC OUTLOOK FOR EUROPE
    GERMANY
    - Increasing need for rapid and accurate diagnostic solutions to promote growth
    FRANCE
    - Growing demand for accessible and convenient diagnostic tools to propel market
    UK
    - Rising number of accredited clinical and hospital laboratories to sustain growth
    ITALY
    - Growing burden of infectious and parasitic diseases to boost market
    SPAIN
    - Rising prevalence of circulatory system diseases to contribute to growth
    REST OF EUROPE
  • 11.4 ASIA PACIFIC
    MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    CHINA
    - Increasing impact of diabetes on public health to amplify growth
    JAPAN
    - Booming geriatric population to stimulate growth
    INDIA
    - Increasing cases of chronic heart and kidney diseases to foster growth
    AUSTRALIA
    - Growing research investments for next-gen point of care devices to boost market
    SOUTH KOREA
    - Growing focus on innovative diagnostic products to drive market
    REST OF ASIA PACIFIC
  • 11.5 LATIN AMERICA
    MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    BRAZIL
    - Increasing public initiatives in healthcare to encourage growth
    MEXICO
    - Need for frequent testing for disease management to expedite growth
    REST OF LATIN AMERICA
  • 11.6 MIDDLE EAST & AFRICA
    GROWING OUTBREAKS OF INFECTIOUS DISEASES AND EMPHASIS ON PREVENTIVE HEALTHCARE TO DRIVE MARKET
    MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 11.7 GCC COUNTRIES
    BOOMING HEALTHCARE INFRASTRUCTURE TO FACILITATE GROWTH
    MACROECONOMIC OUTLOOK FOR GCC COUNTRIES
COMPETITIVE LANDSCAPE
460
  • 12.1 INTRODUCTION
  • 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN POINT OF CARE DIAGNOSTICS MARKET
  • 12.3 REVENUE ANALYSIS, 2021–2023
  • 12.4 MARKET SHARE ANALYSIS, 2023
  • 12.5 COMPANY VALUATION AND FINANCIAL METRICS
  • 12.6 BRAND/PRODUCT COMPARISON
    ABBOTT
    F. HOFFMANN-LA ROCHE LTD.
    NOVA BIOMEDICAL
  • 12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT, KEY PLAYERS, 2023
    - Company footprint
    - Region footprint
    - Mode of purchase footprint
    - Technology footprint
    - Sample footprint
  • 12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
  • 12.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    DETAILED LIST OF KEY STARTUPS/SMES
    COMPETITIVE BENCHMARKING OF STARTUPS/SMES
  • 12.10 COMPETITIVE SCENARIO
    PRODUCT LAUNCHES AND APPROVALS
    DEALS
COMPANY PROFILES
480
  • 13.1 KEY PLAYERS
    ABBOTT
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    SIEMENS HEALTHINEERS AG
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    F. HOFFMANN-LA ROCHE LTD
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    DANAHER
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    QUIDELORTHO CORPORATION
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    BD
    - Business overview
    - Products offered
    - Recent developments
    THERMO FISHER SCIENTIFIC INC.
    - Business overview
    - Products offered
    - Recent developments
    BIOMÉRIEUX
    - Business overview
    - Products offered
    - Recent developments
    BIOSYNEX SA
    - Business overview
    - Products offered
    - Recent developments
    EKF DIAGNOSTICS HOLDINGS PLC
    - Business overview
    - Products offered
    - Recent developments
    TRINITY BIOTECH
    - Business overview
    - Products offered
    - Recent developments
    WERFEN
    - Business overview
    - Products offered
    - Recent developments
    NOVA BIOMEDICAL
    - Business overview
    - Products offered
    - Recent developments
    SEKISUI DIAGNOSTICS
    - Business overview
    - Products offered
    BODITECH MED INC.
    - Business overview
    - Products offered
    - Recent developments
  • 13.2 OTHER PLAYERS
    GRIFOLS, S.A.
    LIFESCAN IP HOLDINGS, LLC
    PTS DIAGNOSTICS
    EUROLYSER DIAGNOSTICA GMBH
    RESPONSE BIOMEDICAL
    ALFA SCIENTIFIC DESIGNS, INC.
    BTNX INC.
    ASCENSIA DIABETES CARE HOLDINGS AG
    FLUXERGY
    PRECISION BIOSENSOR, INC.
    ACON LABORATORIES, INC.
    MENARINI DIAGNOSTICS S.R.L
    ORASURE TECHNOLOGIES, INC.
    MANKIND PHARMA
APPENDIX
555
  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 POINT OF CARE DIAGNOSTICS MARKET: INCLUSIONS AND EXCLUSIONS
  • TABLE 2 POINT OF CARE DIAGNOSTICS MARKET: KEY DATA FROM PRIMARY SOURCES
  • TABLE 3 POINT OF CARE DIAGNOSTICS MARKET: RISK ASSESSMENT
  • TABLE 4 PROJECTED INCREASE OF CANCER PATIENTS, BY REGION, 2022 VS. 2035 VS. 2045
  • TABLE 5 GLOBAL DIABETES ESTIMATES (AGES 20–79) BY REGION, 2021 VS. 2030 VS. 2045 (IN THOUSANDS)
  • TABLE 6 PRODUCT WAIVERS, BY KEY PLAYER, 2021–2024
  • TABLE 7 AVERAGE SELLING PRICE OF POINT OF CARE TESTS, BY PRODUCT, 2022–2024
  • TABLE 8 AVERAGE SELLING PRICE OF GLUCOSE MONITORING TEST STRIPS, BY KEY PLAYER, 2022–2024
  • TABLE 9 AVERAGE SELLING PRICE OF GLUCOSE MONITORING TEST STRIPS, BY REGION, 2022–2024
  • TABLE 10 AVERAGE SELLING PRICE OF INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2022–2024
  • TABLE 11 AVERAGE SELLING PRICE OF CARDIOMETABOLIC MONITORING PRODUCTS, BY REGION, 2022–2024
  • TABLE 12 POINT OF CARE DIAGNOSTICS MARKET: ROLE OF COMPANIES IN ECOSYSTEM
  • TABLE 13 POINT OF CARE DIAGNOSTICS MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2022–2023
  • TABLE 14 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2019–2023 (USD MILLION)
  • TABLE 15 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2019–2023 (USD MILLION)
  • TABLE 16 POINT OF CARE DIAGNOSTICS MARKET: KEY CONFERENCES AND EVENTS, 2025–2026
  • TABLE 17 POINT OF CARE DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
  • TABLE 18 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TECHNOLOGY (%)
  • TABLE 19 KEY BUYING CRITERIA, BY TECHNOLOGY
  • TABLE 20 POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 21 DIABETES-RELATED HEALTH EXPENDITURE PER PERSON, 2021 VS. 2030 VS. 2045 (USD)
  • TABLE 22 POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 23 POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 24 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 25 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 26 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 27 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 28 KEY GLUCOSE MONITORING STRIPS AVAILABLE WORLDWIDE
  • TABLE 29 POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING STRIPS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 30 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING STRIPS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 31 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING STRIPS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 32 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING STRIPS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 33 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING STRIPS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 34 KEY GLUCOSE MONITORING METERS AVAILABLE WORLDWIDE
  • TABLE 35 POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING METERS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 36 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING METERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 37 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING METERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 38 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING METERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 39 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING METERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 40 KEY GLUCOSE MONITORING LANCETS & LANCING DEVICES AVAILABLE WORLDWIDE
  • TABLE 41 POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING LANCETS & LANCING DEVICES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 42 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING LANCETS & LANCING DEVICES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 43 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING LANCETS & LANCING DEVICES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 44 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING LANCETS & LANCING DEVICES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 45 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING LANCETS & LANCING DEVICES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 46 KEY CARDIOMETABOLIC MONITORING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 47 POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 48 POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 49 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 50 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 51 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 52 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 53 POINT OF CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 54 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 55 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 56 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 57 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 58 POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 59 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 60 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 61 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 62 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 63 POINT OF CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 64 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 65 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 66 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 67 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 68 POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 69 POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 70 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 71 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 72 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 73 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 74 POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 75 POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 76 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 77 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 78 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 79 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 80 KEY INFLUENZA TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 81 POINT OF CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 82 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 83 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 84 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 85 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 86 KEY TUBERCULOSIS TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 87 POINT OF CARE DIAGNOSTICS MARKET FOR TUBERCULOSIS TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 88 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR TUBERCULOSIS PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 89 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR TUBERCULOSIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 90 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR TUBERCULOSIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 91 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR TUBERCULOSIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 92 OTHER KEY RESPIRATORY INFECTIONS TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 93 POINT OF CARE DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTION TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 94 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTION PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 95 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 96 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 97 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 98 KEY HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 99 POINT OF CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 100 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 101 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 102 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 103 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 104 KEY TROPICAL DISEASE TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 105 POINT OF CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 106 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 107 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 108 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 109 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 110 POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 111 POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 112 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 113 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 114 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 115 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 116 KEY HIV TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 117 POINT OF CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 118 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 119 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 120 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 121 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 122 POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 123 POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 124 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 125 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 126 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 127 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 128 KEY HEPATITIS B TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 129 POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS B TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 130 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS B TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 131 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS B TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 132 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS B TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 133 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS B TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 134 KEY HEPATITIS C TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 135 POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 136 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 137 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 138 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 139 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 140 KEY SYPHILIS TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 141 POINT OF CARE DIAGNOSTICS MARKET FOR SYPHILIS TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 142 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR SYPHILIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 143 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR SYPHILIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 144 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR SYPHILIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 145 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR SYPHILIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 146 KEY HPV TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 147 POINT OF CARE DIAGNOSTICS MARKET FOR HPV TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 148 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HPV TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 149 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HPV TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 150 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HPV TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 151 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HPV TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 152 KEY CHLAMYDIA TRACHOMATIS TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 153 POINT OF CARE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 154 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 155 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 156 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 157 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 158 POINT OF CARE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHEA TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 159 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHEA TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 160 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHEA TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 161 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHEA TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 162 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHEA TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 163 KEY HSV TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 164 POINT OF CARE DIAGNOSTICS MARKET FOR HSV TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 165 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HSV TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 166 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HSV TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 167 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HSV TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 168 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HSV TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 169 KEY CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 170 POINT OF CARE DIAGNOSTICS MARKET FOR CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 171 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 172 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 173 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 174 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 175 OTHER KEY INFECTIOUS DISEASE TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 176 POINT OF CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 177 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 178 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 179 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 180 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 181 KEY COAGULATION MONITORING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 182 POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 183 POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 184 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 185 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 186 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 187 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 188 POINT OF CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 189 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 190 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 191 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 192 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 193 POINT OF CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 194 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 195 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 196 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 197 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 198 POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 199 POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 200 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 201 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 202 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 203 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 204 KEY PREGNANCY TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 205 POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 206 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 207 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 208 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 209 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 210 KEY FERTILITY TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 211 POINT OF CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 212 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 213 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 214 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 215 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 216 TYPES OF CANCER CASES WORLDWIDE, 2022 VS. 2045
  • TABLE 217 KEY TUMOR/CANCER MARKER TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 218 POINT OF CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 219 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 220 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 221 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 222 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 223 KEY URINALYSIS TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 224 POINT OF CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 225 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 226 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 227 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 228 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 229 KEY CHOLESTEROL TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 230 POINT OF CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 231 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 232 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 233 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 234 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 235 KEY HEMATOLOGY TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 236 POINT OF CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 237 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 238 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 239 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 240 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 241 KEY DRUGS-OF-ABUSE TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 242 POINT OF CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 243 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 244 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 245 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 246 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 247 POINT OF CARE DIAGNOSTICS MARKET FOR THYROID-STIMULATING HORMONE TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 248 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR THYROID-STIMULATING HORMONE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 249 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR THYROID-STIMULATING HORMONE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 250 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR THYROID-STIMULATING HORMONE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 251 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR THYROID-STIMULATING HORMONE TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 252 KEY FECAL OCCULT BLOOD TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 253 POINT OF CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 254 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 255 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 256 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 257 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 258 KEY OTHER POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 259 POINT OF CARE DIAGNOSTICS MARKET FOR OTHER PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 260 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 261 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 262 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 263 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 264 POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
  • TABLE 265 KEY PRESCRIPTION-BASED TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 266 POINT OF CARE DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 267 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 268 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 269 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 270 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 271 KEY OTC TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 272 POINT OF CARE DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 273 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 274 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 275 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 276 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 277 POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 278 KEY BIOCHEMISTRY-BASED POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 279 POINT OF CARE DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 280 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 281 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 282 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 283 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 284 KEY IMMUNOASSAY-BASED POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 285 POINT OF CARE DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 286 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 287 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 288 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 289 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 290 POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 291 POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 292 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 293 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 294 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 295 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 296 KEY RT-PCR-BASED POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 297 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 298 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 299 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 300 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 301 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 302 KEY INAAT-BASED POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 303 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 304 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 305 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 306 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 307 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 308 POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
  • TABLE 309 KEY BLOOD SAMPLE-BASED POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 310 POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 311 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 312 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 313 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 314 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 315 KEY NASAL AND OROPHARYNGEAL SWAB-BASED POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 316 POINT OF CARE DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 317 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 318 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 319 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 320 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 321 KEY URINE SAMPLE-BASED POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 322 POINT OF CARE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 323 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 324 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 325 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 326 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 327 KEY OTHER SAMPLE-BASED POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 328 POINT OF CARE DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 329 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 330 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 331 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 332 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 333 POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 334 POINT OF CARE DIAGNOSTICS MARKET FOR HOME CARE SETTINGS AND SELF-TESTING, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 335 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HOME CARE SETTINGS AND SELF-TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 336 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HOME CARE SETTINGS AND SELF-TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 337 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HOME CARE SETTINGS AND SELF-TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 338 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HOME CARE SETTINGS AND SELF-TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 339 POINT OF CARE DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 340 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 341 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 342 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 343 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 344 POINT OF CARE DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 345 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 346 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 347 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 348 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 349 POINT OF CARE DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES AND PHYSICIAN OFFICES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 350 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES AND PHYSICIAN OFFICES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 351 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES AND PHYSICIAN OFFICES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 352 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES AND PHYSICIAN OFFICES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 353 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES AND PHYSICIAN OFFICES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 354 POINT OF CARE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 355 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 356 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 357 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 358 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 359 POINT OF CARE DIAGNOSTICS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 360 NORTH AMERICA: MACROECONOMIC INDICATORS FOR POINT OF CARE DIAGNOSTICS MARKET
  • TABLE 361 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 362 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 363 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 364 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 365 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 366 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 367 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 368 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 369 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 370 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 371 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
  • TABLE 372 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 373 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 374 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
  • TABLE 375 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 376 NORTH AMERICA: NUMBER OF WOMEN USING HOME PREGNANCY KITS, BY COUNTRY, 2022–2029 (MILLION UNIT)
  • TABLE 377 US: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 378 US: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 379 US: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 380 US: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 381 US: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 382 US: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 383 US: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 384 US: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 385 US: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 386 US: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
  • TABLE 387 US: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 388 US: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 389 US: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
  • TABLE 390 US: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 391 CANADA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 392 CANADA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 393 CANADA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 394 CANADA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 395 CANADA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 396 CANADA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 397 CANADA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 398 CANADA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 399 CANADA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 400 CANADA: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
  • TABLE 401 CANADA: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 402 CANADA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 403 CANADA: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
  • TABLE 404 CANADA: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 405 MACROECONOMIC INDICATORS FOR POINT OF CARE DIAGNOSTICS MARKET IN EUROPE
  • TABLE 406 EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 407 EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 408 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 409 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 410 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 411 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 412 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 413 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 414 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 415 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 416 EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
  • TABLE 417 EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 418 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 419 EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
  • TABLE 420 EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 421 GERMANY: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 422 GERMANY: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 423 GERMANY: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 424 GERMANY: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 425 GERMANY: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 426 GERMANY: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 427 GERMANY: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 428 GERMANY: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 429 GERMANY: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 430 GERMANY: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
  • TABLE 431 GERMANY: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 432 GERMANY: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 433 GERMANY: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
  • TABLE 434 GERMANY: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 435 FRANCE: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 436 FRANCE: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 437 FRANCE: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 438 FRANCE: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 439 FRANCE: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 440 FRANCE: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 441 FRANCE: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 442 FRANCE: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 443 FRANCE: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 444 FRANCE: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
  • TABLE 445 FRANCE: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 446 FRANCE: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 447 FRANCE: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
  • TABLE 448 FRANCE: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 449 UK: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 450 UK: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 451 UK: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 452 UK: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 453 UK: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 454 UK: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 455 UK: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 456 UK: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 457 UK: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 458 UK: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
  • TABLE 459 UK: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 460 UK: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 461 UK: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
  • TABLE 462 UK: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 463 ITALY: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 464 ITALY: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 465 ITALY: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 466 ITALY: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 467 ITALY: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 468 ITALY: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 469 ITALY: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 470 ITALY: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 471 ITALY: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 472 ITALY: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
  • TABLE 473 ITALY: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 474 ITALY: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 475 ITALY: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
  • TABLE 476 ITALY: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 477 SPAIN: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 478 SPAIN: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 479 SPAIN: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 480 SPAIN: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 481 SPAIN: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 482 SPAIN: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 483 SPAIN: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 484 SPAIN: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 485 SPAIN: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 486 SPAIN: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
  • TABLE 487 SPAIN: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 488 SPAIN: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 489 SPAIN: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
  • TABLE 490 SPAIN: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 491 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 492 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 493 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 494 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 495 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 496 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 497 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 498 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 499 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 500 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
  • TABLE 501 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 502 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 503 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
  • TABLE 504 REST OF EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 505 ASIA PACIFIC: MACROECONOMIC INDICATORS FOR POINT OF CARE DIAGNOSTICS MARKET
  • TABLE 506 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 507 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 508 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 509 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 510 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 511 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 512 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 513 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 514 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 515 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 516 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
  • TABLE 517 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 518 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 519 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
  • TABLE 520 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 521 CHINA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 522 CHINA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 523 CHINA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 524 CHINA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 525 CHINA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 526 CHINA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 527 CHINA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 528 CHINA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 529 CHINA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 530 CHINA: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
  • TABLE 531 CHINA: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 532 CHINA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 533 CHINA: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
  • TABLE 534 CHINA: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 535 JAPAN: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 536 JAPAN: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 537 JAPAN: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 538 JAPAN: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 539 JAPAN: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 540 JAPAN: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 541 JAPAN: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 542 JAPAN: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 543 JAPAN: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 544 JAPAN: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
  • TABLE 545 JAPAN: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 546 JAPAN: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 547 JAPAN: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
  • TABLE 548 JAPAN: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 549 INDIA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 550 INDIA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 551 INDIA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 552 INDIA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 553 INDIA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 554 INDIA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 555 INDIA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 556 INDIA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 557 INDIA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 558 INDIA: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
  • TABLE 559 INDIA: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 560 INDIA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 561 INDIA: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
  • TABLE 562 INDIA: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 563 AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 564 AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 565 AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 566 AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 567 AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 568 AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 569 AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 570 AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 571 AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 572 AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
  • TABLE 573 AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 574 AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 575 AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
  • TABLE 576 AUSTRALIA: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 577 SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 578 SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 579 SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 580 SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 581 SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 582 SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 583 SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 584 SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 585 SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 586 SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
  • TABLE 587 SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 588 SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 589 SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
  • TABLE 590 SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 591 REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 592 REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 593 REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 594 REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 595 REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 596 REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 597 REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 598 REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 599 REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 600 REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
  • TABLE 601 REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 602 REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 603 REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
  • TABLE 604 REST OF ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 605 MACROECONOMIC INDICATORS FOR POINT OF CARE DIAGNOSTICS MARKET IN LATIN AMERICA
  • TABLE 606 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 607 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 608 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 609 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 610 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 611 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 612 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 613 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 614 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 615 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 616 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
  • TABLE 617 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 618 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 619 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
  • TABLE 620 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 621 BRAZIL: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 622 BRAZIL: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 623 BRAZIL: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 624 BRAZIL: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 625 BRAZIL: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 626 BRAZIL: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 627 BRAZIL: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 628 BRAZIL: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 629 BRAZIL: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 630 BRAZIL: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
  • TABLE 631 BRAZIL: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 632 BRAZIL: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 633 BRAZIL: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
  • TABLE 634 BRAZIL: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 635 MEXICO: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 636 MEXICO: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 637 MEXICO: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 638 MEXICO: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 639 MEXICO: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 640 MEXICO: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 641 MEXICO: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 642 MEXICO: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 643 MEXICO: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 644 MEXICO: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
  • TABLE 645 MEXICO: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 646 MEXICO: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 647 MEXICO: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
  • TABLE 648 MEXICO: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 649 REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 650 REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 651 REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 652 REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 653 REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 654 REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 655 REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 656 REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 657 REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 658 REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
  • TABLE 659 REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 660 REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 661 REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
  • TABLE 662 REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 663 MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 664 MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 665 MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 666 MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 667 MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 668 MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 669 MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 670 MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 671 MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 672 MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
  • TABLE 673 MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 674 MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 675 MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
  • TABLE 676 MIDDLE EAST & AFRICA: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 677 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
  • TABLE 678 GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 679 GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 680 GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 681 GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 682 GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 683 GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 684 GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 685 GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 686 GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 687 GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION)
  • TABLE 688 GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 689 GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 690 GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022–2029 (USD MILLION)
  • TABLE 691 GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 692 GCC COUNTRIES: MACROECONOMIC INDICATORS
  • TABLE 693 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN POINT OF CARE DIAGNOSTICS MARKET, JANUARY 2021–NOVEMBER 2024
  • TABLE 694 POINT OF CARE DIAGNOSTICS MARKET: DEGREE OF COMPETITION
  • TABLE 695 POINT OF CARE DIAGNOSTICS MARKET: REGION FOOTPRINT
  • TABLE 696 POINT OF CARE DIAGNOSTICS MARKET: MODE OF PURCHASE FOOTPRINT
  • TABLE 697 POINT OF CARE DIAGNOSTICS MARKET: TECHNOLOGY FOOTPRINT
  • TABLE 698 POINT OF CARE DIAGNOSTICS MARKET: SAMPLE FOOTPRINT
  • TABLE 699 POINT OF CARE DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 700 POINT OF CARE DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (1/2)
  • TABLE 701 POINT OF CARE DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2)
  • TABLE 702 POINT OF CARE DIAGNOSTICS MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 703 POINT OF CARE DIAGNOSTICS MARKET: DEALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 704 ABBOTT: COMPANY OVERVIEW
  • TABLE 705 ABBOTT: PRODUCTS OFFERED
  • TABLE 706 ABBOTT: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 707 ABBOTT: DEALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 708 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
  • TABLE 709 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED
  • TABLE 710 SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 711 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 712 SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2021–NOVEMBER 2024
  • TABLE 713 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW
  • TABLE 714 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED
  • TABLE 715 F. HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 716 F. HOFFMANN-LA ROCHE LTD: DEALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 717 F. HOFFMANN-LA ROCHE LTD.: EXPANSIONS, JANUARY 2021–NOVEMBER 2024
  • TABLE 718 DANAHER: COMPANY OVERVIEW
  • TABLE 719 DANAHER: PRODUCTS OFFERED
  • TABLE 720 DANAHER: DEALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 721 QUIDELORTHO CORPORATION: COMPANY OVERVIEW
  • TABLE 722 QUIDELORTHO CORPORATION: PRODUCTS OFFERED
  • TABLE 723 QUIDELORTHO CORPORATION: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 724 QUIDELORTHO CORPORATION: DEALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 725 QUIDELORTHO CORPORATION: EXPANSIONS, JANUARY 2021–NOVEMBER 2024
  • TABLE 726 BD: COMPANY OVERVIEW
  • TABLE 727 BD: PRODUCTS OFFERED
  • TABLE 728 BD: DEALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 729 BD: EXPANSIONS, JANUARY 2021–NOVEMBER 2024
  • TABLE 730 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 731 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
  • TABLE 732 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 733 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 734 BIOMÉRIEUX: COMPANY OVERVIEW
  • TABLE 735 BIOMÉRIEUX: PRODUCTS OFFERED
  • TABLE 736 BIOMÉRIEUX: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 737 BIOMÉRIEUX: DEALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 738 BIOSYNEX SA: COMPANY OVERVIEW
  • TABLE 739 BIOSYNEX SA: PRODUCTS OFFERED
  • TABLE 740 BIOSYNEX SA: DEALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 741 EKF DIAGNOSTICS HOLDINGS PLC: COMPANY OVERVIEW
  • TABLE 742 EKF DIAGNOSTICS HOLDINGS PLC: PRODUCTS OFFERED
  • TABLE 743 EKF DIAGNOSTICS HOLDINGS PLC: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 744 EKF DIAGNOSTICS HOLDINGS PLC: DEALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 745 EKF DIAGNOSTICS HOLDINGS PLC: EXPANSIONS, JANUARY 2021–NOVEMBER 2024
  • TABLE 746 TRINITY BIOTECH: COMPANY OVERVIEW
  • TABLE 747 TRINITY BIOTECH: PRODUCTS OFFERED
  • TABLE 748 TRINITY BIOTECH: PRODUCT APPROVALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 749 TRINITY BIOTECH: DEALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 750 WERFEN: COMPANY OVERVIEW
  • TABLE 751 WERFEN: PRODUCTS OFFERED
  • TABLE 752 WERFEN: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 753 WERFEN: DEALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 754 NOVA BIOMEDICAL: COMPANY OVERVIEW
  • TABLE 755 NOVA BIOMEDICAL: PRODUCTS OFFERED
  • TABLE 756 NOVA BIOMEDICAL: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 757 NOVA BIOMEDICAL: EXPANSIONS, JANUARY 2021–NOVEMBER 2024
  • TABLE 758 SEKISUI DIAGNOSTICS: COMPANY OVERVIEW
  • TABLE 759 SEKISUI DIAGNOSTICS: PRODUCTS OFFERED
  • TABLE 760 BODITECH MED INC.: COMPANY OVERVIEW
  • TABLE 761 BODITECH MED INC.: PRODUCTS OFFERED
  • TABLE 762 BODITECH MED INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 763 BODITECH MED INC.: DEALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 764 BODITECH MED INC.: EXPANSIONS, JANUARY 2021–NOVEMBER 2024
  • TABLE 765 GRIFOLS, S.A.: COMPANY OVERVIEW
  • TABLE 766 LIFESCAN IP HOLDINGS, LLC: COMPANY OVERVIEW
  • TABLE 767 PTS DIAGNOSTICS : COMPANY OVERVIEW
  • TABLE 768 EUROLYSER DIAGNOSTICA GMBH: COMPANY OVERVIEW
  • TABLE 769 RESPONSE BIOMEDICAL: COMPANY OVERVIEW
  • TABLE 770 ALFA SCIENTIFIC DESIGNS, INC.: COMPANY OVERVIEW
  • TABLE 771 BTNX INC.: COMPANY OVERVIEW
  • TABLE 772 ASCENSIA DIABETES CARE HOLDINGS AG: COMPANY OVERVIEW
  • TABLE 773 FLUXERGY: COMPANY OVERVIEW
  • TABLE 774 PRECISION BIOSENSOR, INC.: COMPANY OVERVIEW
  • TABLE 775 ACON LABORATORIES, INC.: COMPANY OVERVIEW
  • TABLE 776 MENARINI DIAGNOSTICS S.R.L: COMPANY OVERVIEW
  • TABLE 777 ORASURE TECHNOLOGIES, INC.: COMPANY OVERVIEW
  • TABLE 778 MANKIND PHARMA: COMPANY OVERVIEW
LIST OF FIGURES
 
  • FIGURE 1 POINT OF CARE DIAGNOSTICS MARKET SEGMENTATION AND REGIONS COVERED
  • FIGURE 2 POINT OF CARE DIAGNOSTICS MARKET: RESEARCH DESIGN
  • FIGURE 3 POINT OF CARE DIAGNOSTICS MARKET: KEY INDUSTRY INSIGHTS
  • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 6 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
  • FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 8 POINT OF CARE DIAGNOSTICS MARKET: TOP-DOWN APPROACH
  • FIGURE 9 POINT OF CARE DIAGNOSTICS MARKET: DATA TRIANGULATION METHODOLOGY
  • FIGURE 10 POINT OF CARE DIAGNOSTICS MARKET: PARAMETRIC ASSUMPTIONS
  • FIGURE 11 POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION)
  • FIGURE 12 POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 13 POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
  • FIGURE 14 POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 15 POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
  • FIGURE 16 POINT OF CARE DIAGNOSTICS MARKET, BY REGION, 2024 VS. 2029 (USD MILLION)
  • FIGURE 17 RISING PREVALENCE OF CHRONIC AND INFECTIOUS DISEASES TO DRIVE MARKET
  • FIGURE 18 GLUCOSE MONITORING PRODUCTS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 19 PRESCRIPTION-BASED TESTING PRODUCTS TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 20 BIOCHEMISTRY SEGMENT TO WITNESS LARGEST MARKET SHARE DURING FORECAST PERIOD
  • FIGURE 21 BLOOD SAMPLES SEGMENT TO COMMAND LARGEST MARKET SHARE DURING FORECAST PERIOD
  • FIGURE 22 HOME CARE SETTINGS AND SELF-TESTING SEGMENT TO HOLD LARGEST MARKET SHARE IN 2029
  • FIGURE 23 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • FIGURE 24 POINT OF CARE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 25 REGIONAL INCIDENCE OF HIV, 2023
  • FIGURE 26 NEW REVENUE POCKETS FOR PLAYERS IN POINT OF CARE DIAGNOSTICS MARKET
  • FIGURE 27 POINT OF CARE DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 28 POINT OF CARE DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 29 POINT OF CARE DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 30 INVESTMENT AND FUNDING SCENARIO, 2021–2024
  • FIGURE 31 POINT OF CARE DIAGNOSTICS MARKET: PATENT ANALYSIS, JANUARY 2014–DECEMBER 2023
  • FIGURE 32 POINT OF CARE DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
  • FIGURE 33 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TECHNOLOGY
  • FIGURE 34 KEY BUYING CRITERIA, BY TECHNOLOGY
  • FIGURE 35 MARKET POTENTIAL OF AI IN POINT OF CARE DIAGNOSTICS MARKET
  • FIGURE 36 PREVALENCE OF DIABETES IN IDF REGIONS AMONG 20–79 YEARS OF ADULTS, 2021 VS. 2045 (%)
  • FIGURE 37 PREVALENCE OF HEART AND CIRCULATORY DISEASE WORLDWIDE, 2021 (MILLION)
  • FIGURE 38 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 39 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 40 REVENUE ANALYSIS OF KEY PLAYERS IN POINT OF CARE DIAGNOSTICS MARKET 2021–2023
  • FIGURE 41 MARKET SHARE ANALYSIS OF KEY PLAYERS IN POINT OF CARE DIAGNOSTICS MARKET, 2023
  • FIGURE 42 EV/EBITDA OF KEY VENDORS, 2024
  • FIGURE 43 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2024
  • FIGURE 44 POINT OF CARE DIAGNOSTICS MARKET: BRAND/PRODUCT COMPARISON
  • FIGURE 45 POINT OF CARE DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 46 POINT OF CARE DIAGNOSTICS MARKET: COMPANY FOOTPRINT
  • FIGURE 47 POINT OF CARE DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 48 ABBOTT: COMPANY SNAPSHOT (2023)
  • FIGURE 49 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2023)
  • FIGURE 50 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2023)
  • FIGURE 51 DANAHER: COMPANY SNAPSHOT (2023)
  • FIGURE 52 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 53 BD: COMPANY SNAPSHOT (2023)
  • FIGURE 54 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 55 BIOMÉRIEUX: COMPANY SNAPSHOT (2023)
  • FIGURE 56 BIOSYNEX SA: COMPANY SNAPSHOT (2023)
  • FIGURE 57 EKF DIAGNOSTICS HOLDINGS PLC: COMPANY SNAPSHOT (2023)
  • FIGURE 58 TRINITY BIOTECH: COMPANY SNAPSHOT (2023)
  • FIGURE 59 WERFEN: COMPANY SNAPSHOT (2023)

 

The study involved major activities in estimating the current market size for the point of care diagnostics market. Exhaustive secondary research was done to collect information on the point of care diagnostics industry. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the point of care diagnostics market.

The four steps involved in estimating the market size are

Secondary Research

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.

The following is a breakdown of the primary respondents:

Point of Care Diagnostics Market

Note 1: Others include sales managers, marketing managers, and product managers.

Note 2: Companies are classified into tiers based on their total revenues. As of 2023, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.

To know about the assumptions considered for the study, download the pdf brochure

COMPANY NAME DESIGNATION
Abbott Regional Sales Manager
F. Hoffmann-La Roche Ltd Product Manager

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the point of care diagnostics market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry have been identified through extensive secondary research
  • The revenues generated by leading players operating in the point of care diagnostics market have been determined through primary and secondary research.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

The research methodology used to estimate the market size includes the following:

Point of Care Diagnostics Market

Data Triangulation

After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Point of care testing (POCT) includes screening or diagnostic tests that are designed to be used at or near the patient's site (such as at home, in an ambulance, at a physician's office, and other locations). POCT allows rapid and reliable diagnostic testing to obtain outcomes instantly, helping physicians/patients make care decisions remotely and as soon as possible.

Stakeholders

  • Senior Management
  • End User
  • Finance/Procurement Department  
  • R&D Department

Report Objectives

  • To define, describe, segment, and forecast the global point of care diagnostics market, by product, mode of purchase, technology, sample, end user, and region
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall point of care diagnostics market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments with respect to six regions, namely, North America, Europe, the Asia Pacific, Latin America, Middle East & Africa, and GCC countries
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
  • To benchmark players within the market using the proprietary Competitive Leadership Mapping framework, which analyzes market players on various parameters within the broad categories of business and product excellence

Previous Versions of this Report

Point of Care Diagnostics Market by Product (Glucose, HIV, Hepatitis C, Pregnancy), Platform (Microfluidics, Dipstick, Immunoassay), Purchase (OTC, Prescription), Sample (Blood, Urine), End User (Pharmacy, Hospital, Homecare) & Region - Global Forecast to 2027

Report Code MD 2702
Published in Feb, 2024, By MarketsandMarkets™

Point of Care/ Rapid Diagnostics Market by Product (Glucose, HIV, Hepatitis C, Pregnancy), Platform (Microfluidics, Dipstick, Immunoassay), Purchase(OTC, Prescription), Sample(Blood, Urine), User (Pharmacy, Hospital, Homecare) - Global Forecast to 2027

Report Code MD 2702
Published in Dec, 2022, By MarketsandMarkets™

Point of Care & Rapid Diagnostics Market by Product (Glucose, Infectious Disease(HIV, Hepatitis C), Pregnancy Test), Platform (Microfluidics, Dipsticks), Mode of Purchase (OTC, Prescription), End User (Pharmacy, Hospital, Home) - Global Forecast to 2027

Report Code MD 2702
Published in Mar, 2022, By MarketsandMarkets™

Point of Care/Rapid Diagnostics Market by Product (Glucose, Infectious Disease (Hepatitis C, Influenza), Coagulation), Platform (Microfluidics, Immunoassay), Mode of Purchase (Prescription, OTC), Enduser (Hospital, e-comm, Home Care) - Global Forecast to 2025

Report Code MD 2702
Published in Feb, 2021, By MarketsandMarkets™

Point of Care Diagnostics Market by Product (Glucose, Infectious Disease (Hepatitis C, Influenza, Respiratory), Coagulation), Platform (Microfluidics, Immunoassays), Mode (Prescription & OTC), End-User (Hospitals, Home Care) - Global Forecast to 2024

Report Code MD 2702
Published in Nov, 2019, By MarketsandMarkets™

Point-of-Care/Rapid Diagnostics Market by Testing (Glucose, Lipids, HbA1c, HCV, HIV, Influenza, Urinalysis, Hematology, Cancer, Pregnancy, PT/INR), Platform (Lateral Flow, Immunoassay), Mode (Prescription, OTC), End-User - Global Forecast to 2022

Report Code MD 2702
Published in Feb, 2018, By MarketsandMarkets™

Point-of-Care Diagnostics Market (Products-Glucose, Cardiometabolic Monitoring, & Infectious Disease Testing Kits, Cardiac & Tumor Markers), (End Users-Home, Hospitals, Ambulatory Care), (Over-the- Counter & Prescription Based) - Global Forecast to 2021

Report Code MD 2702
Published in Jul, 2016, By MarketsandMarkets™

Point-Of-Care Diagnostics / Testing Market by Products (Glucose Monitoring & Infectious Diseases Testing Kits, Cardiac & Tumor Markers), by End Users (Self & Professional Monitoring), Over the Counter & Prescription Based - Global Forecast to 2018

Report Code MD 2702
Published in Sep, 2014, By MarketsandMarkets™
"Our USP is "providing game-changing business opportunities reports with free customization" - so please feel free to provide us with your specific areas of interest / business challenges in much greater detail !!"

We appreciate your interest in this report. Once you fill out the form, you'll be immediately directed to an exclusive solution tailored to your needs. This high-value offering can help boost your revenue by 30% - a must-see opportunity for anyone looking to maximize growth.


By clicking the "Submit" button, you are agreeing to the Terms of Use and Privacy Policy.

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Point of Care Diagnostics Market

DMCA.com Protection Status